Navigation Links
NUCRYST Announces First Quarter 2008 Financial Results
Date:5/6/2008

in 2007. The increase is attributable primarily to nonrecurring costs including severance, stock option expense and third party services.

Foreign Exchange gains in the first quarter of 2008 were $0.6 million compared to foreign exchange losses of $0.2 million in the same period in 2007.

Conference Call

NUCRYST will hold a conference call today, May 6, 2008 at 4:30 p.m. ET, to provide a company update and discuss the financial results for the quarter. The conference call will be simultaneously web cast on NUCRYST's web site and archived for future review until May 13, 2008.

Conference call details:

Date: Tuesday, May 6, 2008

Time: 4:30 PM ET

Dial-in: 866-202-4367 (U.S.); 617-213-8845 (International)

Passcode: 98073917

Webcast: http://www.nucryst.com (Investor Relations section)

To access an audio replay of the call:

Replay Dial-in: 888-286-8010 (U.S.); 617-801-6888 (International)

Replay Passcode: 16575319

About NUCRYST Pharmaceuticals

NUCRYST Pharmaceuticals (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. Smith & Nephew plc sell a range of advanced wound care products under their Acticoat(TM) trade mark. Acticoat(TM) products incorporate NUCRYST's SILCRYST(TM) coatings and are sold in over 30 countries. NUCRYST is also developing pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The Company has developed its proprietary nanocrystalline silver in a powder form, referred to as NPI 32101 for use
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. NUCRYST Announces Management Realignment and R&D Portfolio Change
2. NUCRYST Announces Senior Management Change
3. NUCRYST Pharmaceuticals announces year-end results
4. NUCRYST Pharmaceuticals announces 2007 third quarter results
5. Webcast Advisory - NUCRYST Pharmaceuticals Webcast of Conference Call to Discuss 2007 Third Quarter Results
6. NUCRYST and Smith & Nephew Revise Agreements
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Bank of America Healthcare Conference
8. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
9. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
10. Rigel Announces First Quarter 2008 Financial Results
11. BioForm Medical Announces Extension of Lock-Up Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette M. ... Ginette Collazo, a 15 year veteran of helping drug, biologic and device firms ...
(Date:7/30/2015)... ... , ... Committed to helping the next generation succeed - Mercy College is ... the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative issues a call to ... support they need to think more broadly about their future. Building on what works ...
(Date:7/30/2015)... ... 2015 , ... The Clinical Data Interchange Standards Consortium (CDISC), ... that data standards for clinical research in the areas of Schizophrenia, Hepatitis C ... These three Therapeutic Area (TA) standards were developed per the CDISC global, consensus-based ...
(Date:7/30/2015)... ... ... a healthy head of hair and a feeling of confidence is a powerful one for ... a devastating impact on the daily life of a person. From increased anxiety to ... loss are not to be taken lightly. , The skilled staff at Parsa Mohebi Hair ...
(Date:7/30/2015)... CATHERAL CITY, California (PRWEB) , ... July 30, 2015 , ... ... of substance abuse, clients at Serenity Palms Drug Addiction Treatment Center have created an ... Springs just lost one of its most beloved residents, Rocky Hudson . Hudson ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 2Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 3Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 4Health News:CDISC Releases Clinical Research Data Standards for Schizophrenia, Hepatitis C and Dyslipidemia 5Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 2Health News:Serenity Palms Honors Rocky Hudson, an Advocate of AA and a Beloved Resident of Palm Springs 3
... Best Care Senior,Services has expanded into the Littleton/Denver, ... Service, and Personal,Response Company, is proud to announce ... Care Senior Services for outstanding care. For over ... of our work -- a,sincere concern for the ...
... Blood and Plasma Donor Centers, LENEXA, Kan., ... MEDW ), a provider of ClosedLoop(TM) clinical,systems for ... has,completed the acquisition of substantially all of the ... provider of software products and,services that enable blood ...
... Industry Sales Increase as Consumers Put Their Trust in Natural, Effective ... ... Oct. 31 There has been a profound shift in,the thinking ... become increasingly proactive in seeking more natural means to fight,sickness. As ...
... machinery in a cell to serve their own needs. According ... to gain access to that machinery. , A common target ... or pRb, which serves to block cell division when potentially ... of the retina, this tumor suppressor protein has since been ...
... if drug would have same benefit for Caucasians , , ... cancer with an experimental chemotherapy drug after surgery improved ... , The results of the trial won,t mean much ... S-1, is classified as "investigational" in the United States. ...
... The Medicare bidding,program for durable medical equipment will ... unless Congress modifies,the program. This is the key ... today by the American Association for Homecare.,The Association ... care, choice of provider, and access to the ...
Cached Medicine News:Health News:Announcing Always Best Care Senior Services Expansion Into the Littleton/Denver, Colorado Area 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 3Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:How one virus uses mimicry to replicate successfully 2Health News:Chemo Drug Improves Stomach Cancer Survival for Japanese Patients 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3
(Date:7/30/2015)... July 30, 2015 What can ... Which areas are going to grow at the fastest ... potential revenues to 2025, assessing data, trends, opportunities and ... provides 176 tables, charts, and graphs. Discover the most ... prospects. Our new study lets you assess forecasted sales ...
(Date:7/30/2015)...  Lannett Company, Inc. (NYSE: LCI ) today ... Genuity 35th Annual Growth Conference on Wednesday, August 12, ... Hotel.  A webcast of the presentation ... encouraged to visit the web site at least 10 ... register, download and install any necessary software.  The presentation ...
(Date:7/30/2015)... 2015  Cleave Biosciences today announced that the ... the company a key patent providing the protection ... This newly issued patent, "Fused pyrimidines ... 9,062,026, allows for claims on the composition of ... inhibitor of p97, a critical enzyme that controls ...
Breaking Medicine Technology:Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 2Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 3Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 4Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 5Ophthalmic Devices Market Forecast 2015-2025 - Future Prospects for Leading Companies in Vision Care, Surgical, Diagnostic & Monitoring Devices 6
... , SANTA ... nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, ... core question "Should any vaccines be required for children?" , ... certain vaccinations for children entering public schools. Depending on the ...
... ... Walking for People With All Types of Multiple Sclerosis , ... Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, ... to improve walking speed in people with any type of multiple ...
Cached Medicine Technology:Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 2Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
... System is the next generation ... the symptoms of BPH. This ... the prostate while dilating the ... well tolerated by patients and ...
... proud to announce the release of the OES ... optics with our most commonly used cystoscopy sheaths ... level. Now you can have one instrument that ... the OES Pro cystoscopes offer a superior channel ...
... Defibrillator is a simple "1, 2, ... is compact with a streamline design ... only 13.5 lbs. It rapidly charges ... has full summary pre- & post-event ...
Incontinence Pessaries...
Medicine Products: